<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_5jCVGEA">Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Ping</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karen</forename><forename type="middle">R</forename><surname>Siegel</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mohammed</forename><forename type="middle">K</forename><surname>Ali</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Hubert Department of Global Health and De- partment of Family and Preventive Medicine , Emory University , Atlanta , GA</note>
								<orgName type="department">Hubert Department of Global Health and De- partment of Family and Preventive Medicine</orgName>
								<orgName type="institution">Emory University</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xilin</forename><surname>Zhou</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Boon</forename><forename type="middle">Peng</forename><surname>Ng</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> College of Nursing and Disability, Aging and Technology Cluster , University of Central Florida , Orlando , FL</note>
								<orgName type="department">College of Nursing and Disability, Aging and Technology Cluster</orgName>
								<orgName type="institution">University of Central Florida</orgName>
								<address>
									<settlement>Orlando</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shawn</forename><surname>Jawanda</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Krista</forename><surname>Proia</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xuanping</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Edward</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ann</forename><forename type="middle">L</forename><surname>Albright</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_TkknHrK">Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">1B8C23F25EED97D10FD96C6736E4DE34</idno>
					<idno type="DOI">10.2337/figshare.12081801</idno>
					<note type="submission">Received 23 March 2020 and accepted 3 April 2020</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T13:02+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RT8Ya37">OBJECTIVE</head><p xml:id="_HUhTjnj"><s xml:id="_QmjafgV">To synthesize updated evidence on the cost-effectiveness (CE) of interventions to manage diabetes, its complications, and comorbidities.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_t5f9seC">RESEARCH DESIGN AND METHODS</head><p xml:id="_B2sGahw"><s xml:id="_Knh5bcZ">We conducted a systematic literature review of studies from high-income countries evaluating the CE of diabetes management interventions recommended by the American Diabetes Association (ADA) and published in English between June 2008 and July 2017.</s><s xml:id="_tcPaMFy">We also incorporated studies from a previous CE review from the period 1985-2008.</s><s xml:id="_QN3ZtxD">We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (Â£$25,000 per life year gained [LYG]  or quality-adjusted life year [QALY]), cost-effective ($25,001-$50,000 per LYG or QALY), marginally cost-effective ($50,001-$100,000 per LYG or QALY), or not costeffective (&gt;$100,000 per LYG or QALY).</s><s xml:id="_9pkGwfz">Costs were measured in 2017 U.S. dollars.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2NX3Q7K">RESULTS</head><p xml:id="_5JpeqW7"><s xml:id="_5t9rTQQ">Seventy-three new studies met our inclusion criteria.</s><s xml:id="_BCGWb8x">These were combined with 49 studies from the previous review to yield 122 studies over the period 1985-2017.</s><s xml:id="_CkZGvxU">A large majority of the ADA-recommended interventions remain cost-effective.</s><s xml:id="_Mj9qCh7">Specifically, we found strong evidence that the following ADA-recommended interventions are cost-saving or very cost-effective: In the cost-saving category are 1) ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy for intensive hypertension management compared with standard hypertension management, 2) ACEI/ARB therapy to prevent chronic kidney disease and/or end-stage renal disease in people with albuminuria compared with no ACEI/ARB therapy, 3) comprehensive foot care and patient education to prevent and treat foot ulcers among those at moderate/high risk of developing foot ulcers, 4) telemedicine for diabetic retinopathy screening compared with office screening, and 5) bariatric surgery compared with no surgery for individuals with type 2 diabetes (T2D) and obesity (BMI â¡30 kg/m 2 ).</s><s xml:id="_ZdCx4w2">In the very cost-effective category are 1) intensive glycemic management (targeting A1C &lt;7%) compared with conventional glycemic management (targeting an A1C level of 8-10%) for individuals with newly diagnosed T2D, 2) multicomponent interventions (involving behavior change/education and pharmacological therapy targeting hyperglycemia, hypertension, dyslipidemia, microalbuminuria, nephropathy/retinopathy, secondary prevention of cardiovascular disease with aspirin) compared with usual care, 3) statin therapy compared with no statin therapy for individuals with T2D and history of cardiovascular disease, 4) diabetes self-management education and support compared with usual care, 5) T2D screening every 3 years starting at age 45 years compared with no screening, 6) integrated, patient-centered care compared with usual care, 7) smoking cessation compared with no smoking cessation, 8) daily aspirin use as primary prevention for cardiovascular complications compared with usual care, 9) self-monitoring of blood glucose three times per day compared with once per day among those using insulin, 10) intensive glycemic management compared with conventional insulin therapy for</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="21" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="22" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="23" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="24" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="25" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="26" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="27" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="28" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="29" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="30" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="31" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="32" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="33" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="34" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="35" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="36" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_mZKZBzV"><p xml:id="_r5WcbVv"><s xml:id="_ed86pMV">T2D among adults aged â¡50 years, and 11) collaborative care for depression compared with usual care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_My8Bh4x">CONCLUSIONS</head><p xml:id="_AfTBxv7"><s xml:id="_ZymdyCb">Complementing professional treatment recommendations, our systematic review provides an updated understanding of the potential value of interventions to manage diabetes and its complications and can assist clinicians and payers in prioritizing interventions and health care resources.</s></p><p xml:id="_jsrPRqF"><s xml:id="_zwnEBeS">Diabetes is a serious, common, and costly disease, affecting 34 million Americans (1) and leading to $327 billion <ref type="bibr" target="#b1">(2)</ref> in annual health expenditures in 2017.</s><s xml:id="_hUZkTyE">To better manage and lower the burdens of diabetes, the American Diabetes Association (ADA) annually publishes its Standards of Medical Care in Diabetes (SOC) (3), the most comprehensive and up-to-date clinical knowledge regarding diabetes care.</s><s xml:id="_53Hy7rs">Worldwide, the SOC provides clinicians, patients, researchers, and payers with the most current evidence-based screening, diagnostic, prevention, and management recommendations for diabetes.</s><s xml:id="_hGszGtD">However, the cost-effectiveness (CE) of these strategiesdin other words, the value they provide for these investmentsdvaries greatly and should be considered in management or policy decisions.</s></p><p xml:id="_cZE2V4e"><s xml:id="_su7pZGP">CE analysis is an analytical framework that weighs the benefits and costs of an intervention by comparing it with standard care or other alternatives to see if the value of the intervention justifies its cost.</s><s xml:id="_vzmKSGm">The CE of different treatment options provides critical information to stakeholders at a variety of levels; this information helps in development of optimal treatment strategies or policies to lower current and future health and economic burdens and help determine use of limited health care resources.</s></p><p xml:id="_RZShqP7"><s xml:id="_J6quh5U">In 2010, Li et al. <ref type="bibr" target="#b3">(4)</ref> systematically reviewed all English-language studies published between January 1985 and May 2008 on the CE of diabetes prevention and management interventions recommended by the ADA's SOC 2008 <ref type="bibr" target="#b4">(5)</ref>.</s><s xml:id="_HxFdzVG">The authors concluded that a large majority of the interventions recommended by ADA at that time were cost-saving or very cost-effective.</s><s xml:id="_PKF2rR6">Since then, however, many new technologies and medications have become available and have been added to updated iterations of the ADA's SOC, leading to important changes in the ways diabetes care is delivered, how complications are managed, and the resulting costs.</s><s xml:id="_JBSpjzn">Recently published CE studies on these new technologies and medications can provide evidence on how to prioritize these novel interventions together with older strategies that remain cost-effective.</s></p><p xml:id="_M4mTmu3"><s xml:id="_GveYuUy">To provide up-to-date guidance that aligns with the 2019 SOC (the most up-todate version at the time of data analysis) <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b6">7)</ref>, we aggregated all available data published in English regarding the CE of ADA-recommended interventions to identify diabetes or gestational diabetes mellitus, manage diabetes, screen for diabetes complications, and manage complications and comorbidities.</s><s xml:id="_WXQ3Hyz">We included data from the previous review by Li et al. and systematically added data from the last decade to provide findings that are relevant to contemporary clinical practice.</s><s xml:id="_H3VKR32">The result allows us to assess economic implications of changes that have occurred in the way diabetes care is delivered and how complications are managed.</s><s xml:id="_cyhM9Cz">As a complement to the ADA's 2019 SOC recommendations, findings from this review could assist clinicians and policy makers in selecting interventions that are not only effective but also deliver value.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_u3mgRfu">RESEARCH DESIGN AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_p4whVgm">Data Sources and Literature Search</head><p xml:id="_zTFjvqR"><s xml:id="_wvCg5kH">We followed the same search strategy that was used in the 2010 review by Li et al. <ref type="bibr" target="#b3">(4)</ref>.</s><s xml:id="_7hpmhAX">Briefly, we performed a thorough literature search of seven databases (Cumulative Index to Nursing and Allied Health Literature [CINAHL], Cochrane, EMBASE, MEDLINE, PsycINFO, Scopus, and Sociological Abstracts [Soc Abs]) following the Cochrane Collaboration's protocol <ref type="bibr" target="#b7">(8)</ref> covering the period of June 2008 to July 2017.</s><s xml:id="_XsKXA5w">Medical subject headings matching the previous review's search protocol were selected to create a search strategy.</s><s xml:id="_xZcRX6b">Our search terms were diabetes (indicating the disease of diabetes: "type 1," "type 2," "gestational," "impaired glucose," and "insulin resistance"), costs ("cost or expenditure," "health care cost," "costs or cost analysis"), effectiveness ("benefit" OR "life year" OR "quality-adjusted life years" OR "disability adjusted life years"), costeffectiveness (indicating CE analysis, such as "cost-effectiveness analysis" OR "costutility analysis" OR "economic").</s><s xml:id="_Qr7ruqw">We also screened reference lists of all included articles and publications from leading medical and diabetes-focused journals during the period for additional articles that may have been missed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2BqZd2Q">Article Screening and Selection</head><p xml:id="_wqka65M"><s xml:id="_Zdk9TTV">We included studies from populations in high-income countries (based on World Bank classifications <ref type="bibr" target="#b8">[9]</ref>) that assessed the economic value associated with diabetes management interventions included in the ADA's SOC 2019 <ref type="bibr" target="#b6">(7)</ref>, the most up-to-date version available at the time of our analysis.</s><s xml:id="_sqGva3t">We included studies of patients with undiagnosed or diagnosed diabetes, including type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes mellitus.</s></p><p xml:id="_hZ7kbBv"><s xml:id="_ff38cZr">We included studies that used one of the three major types of economic evaluations: cost-effectiveness analyses, costutility analyses, or cost-benefit analyses, with outcomes measured as cost per additional quality-adjusted life year (QALY) gained, cost per additional life year gained (LYG), or cost per additional disabilityadjusted life year averted.</s></p><p xml:id="_jkARhtk"><s xml:id="_XV7WhST">We included original research studies published in English and excluded review articles, commentaries or letters, conference abstracts, and dissertations.</s><s xml:id="_ZPAWDeX">For this review, we also excluded studies that focused on preventing T2D.</s><s xml:id="_vpnas8X">Each study was screened for eligibility by two authors (K.R.S., X.Zho., B.P.N., S.J., K.P., and X.Zha.</s><s xml:id="_EpvqsWt">all participated in this stage), with disagreements resolved by group discussion and consensus.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NMSXt2f">Data Abstraction</head><p xml:id="_emW5eQY"><s xml:id="_aBxQRsU">For studies from June 2008 through July 2017, we used the same detailed data extraction form used by <ref type="bibr">Li et al. (4)</ref> to systematically gather the following information from each included study: publication information (title, first author's name, publication year), study population, intervention and comparison, study method (within trial versus modeled/ simulation), analytical time horizon and discounting, perspective used, costs, health outcome measures, survey instruments for measuring utility, incremental cost-effectiveness ratio (ICER), whether a sensitivity analysis was conducted, and study conclusion(s).</s><s xml:id="_X6KWuMY">For studies from January 1985 through May 2008, we used the previously abstracted data from Li et al.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WBJGhpm">Quality Assessment of Included Studies</head><p xml:id="_cXtmWza"><s xml:id="_MZYKMkq">To evaluate the quality of the included CE studies, we selected a widely used quality assessment tool based on The BMJ authors' guide for economic studies <ref type="bibr" target="#b9">(10)</ref>, which was used in the 2010 review by Li et al.</s><s xml:id="_YD7chGw">We considered four quality score items: source of cost-specific data, categories of costs, source of benefit-specific data, and categories of benefits.</s><s xml:id="_RQv7es2">We classified studies that did not report all four items as "low quality."</s><s xml:id="_x7BZ7KH">Of studies that had all four components, we assessed nine additional items (analytical time horizon, study perspective, description of the CE model, diagram for constructing the decision tree, currency and year of cost, cost discounting, benefit discounting, ICERs, and sensitivity analysis) for further classification.</s><s xml:id="_ypwK95c">We assigned one point for each item that was reported.</s><s xml:id="_6ZwXE2N">We rated each study as "fair" if it scored 3 or less, "good" if it scored 4-6, and "excellent" if it scored 7-9 points.</s><s xml:id="_vd6EY5F">We restricted our analysis to articles rated as "excellent" or "good" quality.</s><s xml:id="_vn9cHJt">Our quality assessment methodology mirrored that used by Li et al. Figure <ref type="figure">1</ref> illustrates the complete process for screening articles.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_nbJPPgY">Data Analysis and Synthesis</head><p xml:id="_zDGEyMJ"><s xml:id="_rkaqqUM">To synthesize findings, we first grouped articles into four broad categories: 1) screening for undiagnosed diabetes (including T2D and gestational diabetes mellitus), 2) managing diabetes and risk factors to prevent diabetes-related complications (comprehensive lifestyle interventions; diabetes self-management education [DSME]; self-monitoring of blood glucose [SMBG]; intensive glycemic, blood pressure, and lipid control; integrated and coordinated care; smoking cessation), 3) screening for and early treatment of diabetes complications (cardiovascular disease [CVD], eye complications, foot ulcers, end-stage renal disease [ESRD]), or 4) treating diabetes-related complications and comorbidities (CVD, eye complications, foot ulcers, and comorbidities such as obesity, mental health, and sleep apnea).</s><s xml:id="_vbUkJN3">Within each of the four broader groups, we further classified studies into specific categories corresponding to each ADA-recommended intervention.</s></p><p xml:id="_FjfqAqG"><s xml:id="_qm3Mazw">To facilitate comparisons across studies, we converted all costs and ICERs to 2017 U.S. dollars using the Consumer Price Index <ref type="bibr" target="#b10">(11)</ref>.</s><s xml:id="_2psUTRd">If costs were reported in other currencies, we used the annual exchange rate from the Federal Reserve Bank <ref type="bibr" target="#b11">(12)</ref> to convert them into U.S. dollars.</s><s xml:id="_Ds9XAyM">If a study did not mention the year used in cost calculations, we assumed cost was for the one year prior to publication.</s><s xml:id="_WzSM6Ty">ICERs were expressed as dollars per QALY or dollars per LYG and were rounded to the nearest hundred dollars.</s><s xml:id="_wTAxjFP">We calculated a range and median ICER for each intervention category.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_56HhGdQ">Classifying the Interventions</head><p xml:id="_XduHJaD"><s xml:id="_dZTpVBj">We classified interventions based on their median levels of CE (five tiers) and strength of evidence (three levels).</s><s xml:id="_387adYN">As there are no universally accepted thresholds to judge whether an intervention is cost-effective, we grouped the CE tiers of the intervention based on conventional norms according to their estimated ICERs: 1) cost-saving when the intervention generates better health outcomes and costs less than the comparison intervention or is cost neutral (ICER 5 0), 2) very cost-effective if the ICER is greater than zero but less than or equal to $25,000 per QALY or LYG, 3) cost-effective if the ICER is greater than $25,000 but less than or equal to $50,000 per QALY or LYG, 4) marginally costeffective if the ICER is greater than $50,000 but less than or equal to $100,000 per QALY or LYG, and 5) not cost-effective if the ICER is greater than $100,000 per QALY or LYG.</s><s xml:id="_PNwWnC6">Since there are no conventional norms for thresholds of cost per LYG, we used the same threshold for cost per QALY, which was the same approach used by Li et al. <ref type="bibr" target="#b3">(4)</ref>.</s></p><p xml:id="_gEg4bUu"><s xml:id="_dF8CGr6">We classified the evidence level of the CE findings as strong, supportive, or uncertain.</s><s xml:id="_bEfkU6V">Strong evidence included findings from one of the following two categories:</s></p><p xml:id="_jxGP8JW"><s xml:id="_AxASEZq">Category 1: 1.</s><s xml:id="_HYyuBXC">The CE of the intervention was evaluated by two or more studies, AND 2. these studies were rated as at least "good" in quality, AND 3. the effectiveness of the interventions was based on either well-conducted, generalizable randomized clinical trials with adequate power or wellconducted meta-analyses or a diabetes disease simulation model that was validated, AND 4. the effectiveness of the intervention was also rated as level A or level B evidence by the ADA's SOC 2019 (13), AND 5. the ICERs of the intervention from different studies consistently fell into the same CE tier.</s></p><p xml:id="_nsJKbbU"><s xml:id="_twD2xyn">Category 2: 1. CE assessment meets items 3 and 4 from category 1, but only one study evaluated the intervention, AND 2. the study was rated as "excellent" in quality.</s></p><p xml:id="_CP4q9dr"><s xml:id="_gkGwBxC">We considered evidence on the CE of an intervention to be supportive if:</s></p><p xml:id="_HdCXyyy"><s xml:id="_ZGPrqWM">1. the CE of the intervention was evaluated by only one study AND this study was rated lower than "excellent" quality, OR</s></p><p xml:id="_wjWR2Te"><s xml:id="_F7JYVdE">Figure 1-Flowchart for article inclusion.</s><s xml:id="_Qk9MRxb">care.diabetesjournals.org</s><s xml:id="_KgKpQp7">Siegel and Associates 1559 2. the effectiveness of the intervention was supported by level C evidence according to the ADA's SOC 2019 (13) or by expert consensus only, OR 3. the CE was based on a simulation by a diabetes disease model that was not validated (a model was considered to be validated if it was explicitly stated in the text of the article or if the model was known to be validated based on previous literature).</s></p><p xml:id="_FS4YMAB"><s xml:id="_WQpSPPs">For each ADA-recommended intervention within each evidence-CE level category, we described its comparison intervention, the study population in which the intervention was implemented, and the ADA's level of evidence rating.</s><s xml:id="_Qwk3aQF">We also reported the number of studies that evaluated the CE of this intervention (based on the current evidence and on the previous review), and the median and range of the ICERs across the studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_v7xPzru">RESULTS</head><p xml:id="_pr86nnu"><s xml:id="_HnqANRS">Our initial search yielded 18,195 articles over the period of June 2008 to July 2017.</s><s xml:id="_bU5u3xT">After removal of duplicates and screening of all abstracts, 1,445 articles remained, of which we reviewed full texts to identify 73 CE studies that met our inclusion criteria.</s><s xml:id="_s9ARHn7">We added the 49 relevant studies on diabetes management from the 2010 review by <ref type="bibr">Li et al. (encompassing 1985</ref><ref type="bibr">Li et al. (encompassing -2008))</ref>, bringing the total number of studies to 122 over the period 1985-2017 (Fig. <ref type="figure">1</ref>).</s><s xml:id="_sWr5wkw">Table <ref type="table" target="#tab_1">1</ref> describes the CE studies included in our final review by intervention category.</s><s xml:id="_fWw68EF">Studies that evaluated multiple interventions or a single intervention in diverse subgroups were assigned to more than one intervention or population category, respectively.</s><s xml:id="_gSk3wPa">Supplementary Fig. <ref type="figure">1</ref> provides a summary of the numbers of studies across the four broad intervention categoriesd screening for undiagnosed diabetes (8 studies), managing diabetes and risk factors to prevent diabetes-related complications (71 studies), screening for and early treatment of diabetes complications (33 studies), and treating diabetes-related complications and comorbidities (19 studies)das well as how the number of articles in each category changed from the previous review  to the current review .</s><s xml:id="_vr6TxjZ">Except for smoking cessation, the number of articles in every category increased over time, and five new categories emerged: preventing CVD complications, treating CVD complications, and addressing comorbidities of obesity, mental health, and sleep apnea.</s></p><p xml:id="_B4cvaG9"><s xml:id="_uzNCPmY">In Table <ref type="table">2</ref>, we classified each of the ADA-recommended interventions based on their levels of CE and strength of evidence by intervention category, using all studies over the period 1985-2017.</s><s xml:id="_Dj5YCwK">To facilitate use by clinicians and decision makers, we describe the findings across each of the four intervention categories from a health system perspective.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_BnnmhNG">Strong Evidence</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_htwJypp">Screening for Undiagnosed Diabetes</head><p xml:id="_y8qttrM"><s xml:id="_WDwCjbe">Screening for T2D every 3 years starting at age 45 years for the U.S. population without diabetes, compared with no screening, had strong evidence of being very cost-effective at $7,898/QALY (every 1 year compared with every 3 years was also very cost-effective at $8,139/ QALY).</s><s xml:id="_FsJH4Xd">On the other hand, there was strong evidence that universal opportunistic screening for undiagnosed T2D among the U.S. population (whether or not followed by treatment), compared with targeted screening in high-risk individuals, was not cost-effective (.$100,000/QALY).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jnCaxAP">Managing Diabetes and Risk Factors to Prevent Diabetes-Related Complications</head><p xml:id="_DkDk5Hw"><s xml:id="_zRBYy26">For interventions to manage diabetes and risk factors to prevent complications, the evidence was mixed.</s><s xml:id="_N9GdsZY">We found strong evidence that DSME for individuals with diabetes, compared with usual care, is very cost-effective ($5,047/QALY).</s><s xml:id="_fgcJa9x">Additionally, there were several new studies on the daily frequency of SMBG, which led to the new finding that SMBG three times per day, compared with SMBG once per day, is very cost-effective ($3,719/QALY) among adults with T2D currently taking insulin.</s></p><p xml:id="_WEWmaNK"><s xml:id="_zYPZ4wR">The ICERs for intensively managing glycemia varied according to a patient's age, duration of diabetes, and diabetes type (1 or 2).</s><s xml:id="_8teKcfF">We found that intensive glycemic management compared with conventional management was very costeffective among young individuals with newly diagnosed T2D ($4,318/QALY) and older individuals (aged $50 years) with T2D ($15,398/QALY) and was costeffective when given to individuals with T1D regardless of age ($41,339/QALY).</s></p><p xml:id="_45sRfWN"><s xml:id="_4EP9Tw3">For blood pressure management, ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapies, used either for intensive hypertension management (compared with suboptimal blood pressure management) or to prevent chronic kidney disease and/or ESRD in patients with albuminuria, compared with no ACEI/ARB therapy, emerged with strong evidence of being cost-saving.</s></p><p xml:id="_YpUGnhQ"><s xml:id="_vFdjE83">Over the period 1985-2017, studies comparing multicomponent interventions (including behavior change and medication adherence to improve glycemia, blood pressure/CVD, lipids, and nephropathy/retinopathy prevention and screening together) with usual care have shown a range of value achieved from cost-effective to cost-saving.</s><s xml:id="_G33CCHb">Overall, however, we found that these multicomponent interventions were on average very cost-effective ($2,315/QALY) for individuals with T1D and T2D compared with usual care.</s></p><p xml:id="_eMQVC5x"><s xml:id="_VJwtytw">Diabetes management interventions that remained consistent with the previous review as very cost-effective were 1) integrated, patient-centered care based on the Chronic Care Model for individuals with T2D compared with usual care ($11,339/QALY), and 2) smoking cessation for individuals with diabetes compared with no smoking cessation (,$31,750/ QALY).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_CKaDAQs">Screening for and Early Treatment of Diabetes-Related Complications</head><p xml:id="_9KpxJ5R"><s xml:id="_PSYwRYZ">We found strong evidence for two costsaving screening and early treatment interventions: 1) comprehensive foot care and patient education to prevent and treat foot ulcers among individuals with diabetes and at moderate/high risk of developing foot ulcers, compared with usual care, and 2) telemedicine for diabetic retinopathy screening among individuals with diabetes compared with office screening for diabetic retinopathy.</s><s xml:id="_XR8jw4V">Additionally, we found strong evidence that screening for eye complications every 1-2 years for individuals with diabetes, compared with no screening, is very cost-effective ($8,763/QALY).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_h9JhXnh">Treatment of Diabetes-Related Complications and Comorbidities</head><p xml:id="_uyG4SrV"><s xml:id="_ecqNcKX">Statin therapy for secondary prevention of CVDdi.e., in individuals with T2D and a history of CVDdcompared with no statin therapy remained consistent from the previous review as very cost-effective ($4,627/ QALY), while among individuals with T2D, hyperlipidemia, and no history of CVD, statin therapy was marginally costeffective ($67,873/QALY).</s><s xml:id="_CtT5pAp">A new finding in this review was that daily aspirin use for primary prevention of CVD among individuals with T2D, compared with usual care, was very cost-effective ($2,395/QALY).</s><s xml:id="_6QGvDNW">There were eight studies evaluating the CE of bariatric surgery in individuals with T2D and obesity (BMI $30 kg/m 2 ) compared with no bariatric surgery.</s><s xml:id="_vA4EQYy">All eight studies found this intervention to be cost-saving.</s><s xml:id="_uWQHRts">Additionally, three studies evaluated the CE of collaborative care models to comanage depression in individuals with T2D and depression compared with usual care and found such treatment to be very cost-effective ($18,814/QALY).</s></p><p xml:id="_QaZfr29"><s xml:id="_ZEfPkQ7">Studies on two new ADA-recommended drugs (ranibizumab for diabetic retinopathy and duloxetine for painful diabetic peripheral neuropathy) were also included in this review.</s><s xml:id="_8Muc3wK">Bothdranibizumab compared with panretinal photocoagulation and duloxetine compared with desipraminedwere found to be marginally cost-effective ($51,008/QALY and $67,188/QALY, respectively).</s><s xml:id="_y3J2Qqf">There were three specific interventions in the "uncertain evidence" category: 1) screening a 30-year-old pregnant woman between 24-28 weeks' gestation (base case) for gestational diabetes mellitus compared with no screening (cost-saving); 2) SMBG once per day and provision of monitoring devices and strips for individuals with T1D and for those with T2D not using insulin compared with usual care (SMBG once per day without provision of devices and strips), at .$100,000/QALY; and 3) computerized decision-support systems linked to electronic health records and shared between patients and physicians ($190,417/QALY).</s><s xml:id="_b5SpkU6">lead to better allocation of health care resources.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2UCs4j7">CONCLUSIONS</head><p xml:id="_Nfd2wnQ"><s xml:id="_DkXqJpe">Figure <ref type="figure" target="#fig_2">2</ref> is a comprehensive guide to our findings.</s><s xml:id="_XQ3yUPe">Overall, the ADA-recommended interventions included in the previously published review remain cost-saving, very cost-effective, or cost-effective.</s><s xml:id="_9Phvedu">The strength of the evidence improved from supportive to strong for both DSME (compared with usual care) and integrated, patient-centered care based on the Chronic Care Model (compared with usual care) due to additional studies on these topics during the 2008-2017 time period.</s><s xml:id="_zHJ2hv2">Interventions that are cost-saving should be implemented, and those that are very cost-effective or cost-effective based on strong evidence warrant consideration for implementation.</s><s xml:id="_Zg7Beqf">ADArecommended interventions rated as cost-saving, very cost-effective, or costeffective with supportive evidence should be adopted if extra resources are available or if similar interventions with strong evidence are unavailable or infeasible in a specific setting.</s></p><p xml:id="_ResCyFj"><s xml:id="_cHDFkFm">Our review highlighted the value associated with new and innovative interventions to manage and treat diabetes, including technology-related innovations and those focused on addressing diabetes-related comorbidities.</s><s xml:id="_zDWAv34">The focus on technological innovations and diabetes-related comorbidities is well-aligned with the ADA SOC 2019 (14) (as well as the recently updated ADA SOC 2020 <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b13">14]</ref>).</s><s xml:id="_PrQs7V7">In addition, the inclusion of collaborative care models for depression is a big step toward acknowledging and addressing the comorbid conditions of diabetes and depression, which is increasingly being seen as an important consideration in the care of people with diabetes <ref type="bibr" target="#b14">(15)</ref>.</s></p><p xml:id="_f7Qbwy5"><s xml:id="_qXK7GS8">Multicomponent interventions are also featured prominently in the current review and may have implications for delivery system design, especially in the context of persistent gaps in achievement of diabetes care goals <ref type="bibr" target="#b15">(16,</ref><ref type="bibr" target="#b16">17)</ref>.</s><s xml:id="_2SnbBfy">Among individuals with diabetes, interventions that included a combination of practice change, behavior change and education, pharmacologic therapy targeting hyperglycemia, hypertension, dyslipidemia, microalbuminuria, or nephropathy/retinopathy, and secondary prevention of CVD with aspirin were very cost-effective compared with usual care, based on strong evidence.</s><s xml:id="_XaAz7Sw">Of note, our review predates the ASCEND (A Study of Cardiovascular Events in Diabetes) trial, which showed that the primary CVD prevention benefits of aspirin were offset by the increased risk of major bleeding events <ref type="bibr" target="#b17">(18)</ref>.</s></p><p xml:id="_fzNeJMm"><s xml:id="_2RB6b5N">In some cases, CE evaluations may help to provide more insight into how ADArecommended interventions might be prioritized for specific populations receiving the intervention.</s><s xml:id="_WzyTpPr">For example, bariatric surgery was cost-saving among individuals with T2D and obesity but only very cost-effective among individuals with T2D and overweight, likely due to larger health risks posed by obesity.</s><s xml:id="_7mwztEH">We also noted differences in the CE of statin therapy for individuals with diabetes with and without CVD; when used as secondary prevention, there is clear value to statin use (cost-saving).</s><s xml:id="_A7qCPBa">However, for primary prevention, statin use has been found to be less cost-effective.</s><s xml:id="_W6pxqQd">We found that the CE of intensive glycemic management (with a goal of reducing A1C values) depends on age and duration since diabetes diagnosis.</s><s xml:id="_8wBxmsM">Among young individuals with newly diagnosed T2D, intensive glycemic management, compared with conventional insulin therapy, is costsaving; indeed, recent research shows that earlier intensive management is associated with lower long-term risk of complications <ref type="bibr" target="#b18">(19)</ref>.</s><s xml:id="_AjGVvRW">For older individuals (aged $50 years) with T2D and shorter life expectancy, the ability to see benefits of intensive glycemic management is limited, in part because cardiovascular or mortality benefits may not be seen for at least 10 years <ref type="bibr" target="#b19">(20)</ref>.</s><s xml:id="_tHvdfDf">In individuals with T1D, intensive glycemic management compared with conventional insulin therapy remains cost-effective.</s></p><p xml:id="_hwZAPne"><s xml:id="_eTynmTy">There are a few key areas that future economic evaluations of diabetes should consider.</s><s xml:id="_WGYkUQh">First, more studies are needed to evaluate the CE of interventions that fell in the "supportive" or "uncertain" evidence categories.</s><s xml:id="_pfM7auv">In cases where interventions have uncertain value due to a small number of studies (i.e., incomplete knowledge), adding to the evidence base could help to clarify their value.</s><s xml:id="_brZBYs7">There are also a number of new, efficacious medications and treatments for the management of glycemia (glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors), lipids (PSK9 inhibitors), and heart failure (sacubitril/valsartan [Entresto]) that were not included in this review because there are no published CE studies.</s><s xml:id="_gZeV496">For studies with weaker efficacy data, further efficacy studies are needed.</s></p><p xml:id="_QKCjn4P"><s xml:id="_SRqw8SV">Second, more studies are needed that address interventions in real-world settings, as our current review is predominantly based on randomized controlled trials or computer simulation models.</s><s xml:id="_Xampd74">In real life, however, there are many factors to consider in addition to the CE of an intervention, such as 1) coverage for the intervention in question (determine access), 2) motivation (side effects or mode of delivery [e.g., injectable versus oral] may deter patients from taking specific medications), and 3) whether the risk reduction in real life is similar to what was observed in trials and models (i.e., effectiveness versus efficacy).</s><s xml:id="_Rd4mw2u">These are many of the unknowns that clinicians and policy makers must consider as they attempt to use the data from this review in practice.</s></p><p xml:id="_J5FYjTA"><s xml:id="_mx5tzMa">Third, there may be additional costeffective interventions that exist but have not been studied or about which the right questions are not being asked.</s><s xml:id="_CKZt7DZ">For example, the 2010 review included one article regarding the CE of smoking cessation, which was found to be very cost-effective.</s><s xml:id="_Cq6TP3J">There were no additional articles in this category from 2008-2017, likely because it is universally understood that smoking cessation is good and thus no one would be compelled to argue its value; a more interesting contemporary economic question might be to inquire how often a smoking cessation intervention should be implemented for it to be most costeffective and most adoptable by clinicians and their patients.</s></p><p xml:id="_RUGm9Mj"><s xml:id="_qXspWrv">The CE of an intervention in decisionmaking is important, but it is not the only factor to consider.</s><s xml:id="_ZqfDecy">CE analysis does not address equity in the distribution of costs and the benefits of an intervention, societal or personal willingness to pay, social and legal aspects, or ethical issues associated with each intervention.</s><s xml:id="_7Yq6V5q">However, with an eye toward finding diabetes management and treatment interventions that can best increase the value of our health care dollars, this review of the most up-to-date available evidence can help to guide clinicians and policymakerstowardthemostcost-effective use of their prescriptions and health care dollars.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc><div><p xml:id="_AxcKF8h"><s xml:id="_8sREz98">Supportive and Uncertain EvidenceThere were nine specific interventions for which the level of CE was based on supportive evidence.</s><s xml:id="_MvTArby">Among these, costsaving interventions are 1) reimbursement for ACEI by public insurance for individuals with diabetes compared with paying out of pocket and 2) group-based peer support for individuals with T2D compared with usual care.</s><s xml:id="_fc5cM6j">Very cost-effective interventions, based on supportive evidence, were both new findings in this updated review: 1) statin treatment at T2D diagnosis compared with no lipid-regulating treatment ($3,294/QALY) and 2) bariatric surgery for individuals with T2D and overweight compared with no surgery ($23,320/QALY).</s><s xml:id="_4E59hgH">Continuous positive airway pressure (CPAP) therapy for individuals with T2D and obstructive sleep apnea compared with usual care was also costeffective ($27,750/QALY).</s><s xml:id="_CWpsGJA">Adhering to the National Cholesterol Education Program Adult Treatment Panel III guidelines for adults with T2D and mixed dyslipidemia compared with usual care was marginally cost-effective ($67,873/QALY).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><figDesc><div><p xml:id="_aQ6mPAH"><s xml:id="_cznT22J">Oursystematicreviewprovidesanupdated understanding of the potential value of interventions to manage and treat diabetes from a health system perspective.</s><s xml:id="_G6GT969">Since the last review in 2010, the evidence that interventions to manage diabetes are cost-effective has grown in terms of additional evaluations to bolster existing evidence, as well as new economic evaluations of novel interventions and methods of care delivery.</s><s xml:id="_BD9vehv">ACEI/ARB therapy compared with standard hypertension management, comprehensive foot care compared with usual care, and intensive glycemic management compared with conventional therapy are confirmed as very cost-effective interventions, while multicomponent interventions compared with usual care, statin therapy for secondary prevention compared with no statin therapy, T2D screening every 3 years compared with no screening, and screening for eye complications compared with no screening are confirmed as very costeffective interventions.</s><s xml:id="_CRBP4Yf">New findings include telemedicine for diabetic retinopathy screening and bariatric surgery for type 2 diabetes and BMI $30 kg/m 2 as cost-saving interventions and aspirin use for primary prevention of cardiovascular complications, SMBG three times per day for insulin-treated patients (compared with once per day), intensive glycemic management among those aged $50 years, and collaborative care for depression as very cost-effective interventions.</s><s xml:id="_9R5qDgW">This review complements professional treatment recommendations and can assist clinicians and payers in prioritizing interventions in an evidence-based manner that may</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 -</head><label>2</label><figDesc><div><p xml:id="_UfMe2Rr"><s xml:id="_KsWYeTc">Figure 2-Summary of the CE of interventions (strong evidence only).</s><s xml:id="_g4KnySj">CKD, chronic kidney disease; DM, diabetes; DR, diabetic retinopathy; PDPN, painful diabetic peripheral neuropathy; undx, undiagnosed.</s></p></div></figDesc><graphic coords="31,51.65,72.23,476.55,210.16" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><figDesc><div><p xml:id="_CTfyNRt"><s xml:id="_GUd28A3">94. Dong FB, Sorensen SW, Manninen DL, et al.</s><s xml:id="_Su4D6tP">Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.</s><s xml:id="_Yjz9FUA">Pharmacoeconomics 2004;22:1015-1027 95.</s><s xml:id="_WgD7NQ9">Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.</s><s xml:id="_yXjjHbh">An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.</s><s xml:id="_Qx98d4z">J Hum Hypertens 2004;18: 733-738 96.</s><s xml:id="_YfdHmzu">Palmer AJ, Annemans L, Roze S, et al.</s><s xml:id="_EKxwKgg">Costeffectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.</s><s xml:id="_fPKZ37m">Diabetes Care 2004;27:1897-1903 97.</s><s xml:id="_6ZbGrtW">Szucs TD, Sandoz MS, Keusch GW.</s><s xml:id="_Kur7eHr">The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerlanddan analysis of the RENAAL study.</s><s xml:id="_SyJAhAp">Swiss Med Wkly 2004;134:440-447 98. Palmer AJ, Annemans L, Roze S, et al.</s><s xml:id="_PFg3JPQ">Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.</s><s xml:id="_Medemrh">Kidney Int Suppl 2005;67(Suppl.</s><s xml:id="_CF3EyAS">93): S52-S54 99.</s><s xml:id="_J7DutdY">Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.</s><s xml:id="_5s6nSB7">Ann Intern Med 2005;143:89-99 100.</s><s xml:id="_kVjZS9a">Coyle D, Rodby R, Soroka S, et al.</s><s xml:id="_e7nB62p">Costeffectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.</s><s xml:id="_ZU9BwzM">Clin Ther 2007;29: 1508-1523 101.</s><s xml:id="_3zvA5ND">Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.</s><s xml:id="_vEpnrJa">Eur J Health Econ 2007;8:161-168 102.</s><s xml:id="_xsQ57HP">Palmer AJ, Valentine WJ, Ray JA.</s><s xml:id="_DweEkhv">Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.</s><s xml:id="_9jD2Ap8">Int J Clin Pract 2007;61:1626-1633 103.</s><s xml:id="_NCYbDxR">Gaede P, Valentine WJ, Palmer AJ, et al.</s><s xml:id="_Q5XfvMB">Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.</s><s xml:id="_USbUaxg">Diabetes Care 2008;31:1510-1515 104.</s><s xml:id="_Hs3aAk9">Tasosa J, Schuster R, McAlearney JS.</s><s xml:id="_jc7tZH7">Costeffectiveness of treating hypertension, hyperglycemia, and hyperlipidemia in African Americans and the general population with type 2 diabetes.</s><s xml:id="_GucdBhp">J Health Care Poor Underserved 2010;21:161-176 105.</s><s xml:id="_Wu6TmMy">Giorda CB, Nicolucci A, Pellegrini F, et al.</s><s xml:id="_fNvSYPX">Improving quality of care in people with type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term costeffectiveness analysis.</s><s xml:id="_4uf2uts">Diabet Med 2014;31: 615-623 106.</s><s xml:id="_baNPAvw">Laxy M, Wilson ECF, Boothby CE, Griffin SJ.</s><s xml:id="_hPZXb6A">Incremental costs and cost effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: an update with empirical trial-based cost data.</s><s xml:id="_bpN5e5Y">Value Health 2017;20:1288-1298</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="3,50.91,500.71,312.80,234.82" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_ukmDRZh"><s xml:id="_eAkfGvV">Description of the CE studies for diabetes interventions AIIRA, angiotensin II receptor antagonist; AusDiab, Australian Diabetes, Obesity, and Lifestyle Study; BP, blood pressure; CABG, coronary artery bypass graft; CDSS, clinical decision support system; CHD, coronary heart disease; DCCT, Diabetes Control and Complications Trial; DRVS, Diabetic Retinopathy Vitrectomy Study; ECG, electrocardiogram; EMR, electronic medical record; FPG, fasting plasma glucose; DM, diabetes; DME, diabetic macular edema; DPP, Diabetes Prevention Program; DPP-4, dipeptidyl peptidase 4; DR, diabetic retinopathy; GCT, glucose challenge test; GDM, gestational diabetes mellitus; GP, general practitioner; GTT, glucose tolerance test; HMO, health maintenance organization; IADPSB, International Association of the Diabetes and Pregnancy Study Groups; ISO, International Organization for Standardization; IT, information technology; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; max, maximum; OGTT, oral glucose tolerance test; PHQ, patient health questionnaire; preDM, prediabetes; QALE, quality-adjusted life expectancy; RCT, randomized controlled trial; TZD, thiazolidinedione; UKPDS, UK Prospective Diabetes Study.</s><s xml:id="_ZxvQWQ9">American Diabetes Association Standards of Care 2018; DM, diabetes; DME, diabetic macular edema; DR, diabetic retinopathy; EHR, electronic health record; PDPN, painful diabetic peripheral neuropathy.</s><s xml:id="_pfXMDn3">Costsaving is defined as an intervention that generates a better health outcome and costs less than the comparison intervention or is cost neutral (ICER $100,000 per QALY or LYG; or not cost-effective, .$100,000</s><s xml:id="_JnG39Yp">per QALY or LYG.</s><s xml:id="_sMvabSN">A, as defined in Standards of Care 2018: clear evidence from well-conducted, generalizable, randomized controlled trials that are adequately powered; compelling nonexperimental evidence, i.e., "all or none" rule developed by the Centre for Evidence-Based Medicine at Oxford; supportive evidence from well-conducted randomized controlled trials that are adequately powered.</s><s xml:id="_RZ7d6Es">B, as defined in Standards of Care 2018: supportive evidence from well-conducted cohort studies; supportive evidence from a well-conducted case-control study.</s><s xml:id="_5ZZZHa9">C, as defined in Standards Care 2018: supportive evidence from poorly controlled or uncontrolled studies; conflicting evidence with the weight of evidence supporting the recommendation.</s><s xml:id="_MRSKGEf">E, as defined in Standards of Care 2018: expert consensus or clinical experience.</s></p></div></figDesc><table><row><cell></cell><cell>ICER (in 2017 US$)</cell><cell></cell><cell>$114,046/QALY</cell><cell></cell><cell></cell><cell></cell><cell>$59,436-$165,735/QALY,</cell><cell>decreasing with age</cell><cell>$89,535/QALY for age 45 years</cell><cell>$91,694-$240,157/QALY,</cell><cell>decreasing with age</cell><cell>$233,045/QALY for age 45 years</cell><cell>$273,812-$888,746/QALY</cell><cell>increasing with age</cell><cell></cell><cell>$2,088/QALY</cell><cell></cell><cell></cell><cell></cell><cell>$4,301/QALY</cell><cell></cell><cell></cell><cell></cell><cell>$14,807/QALY</cell><cell></cell><cell>$21,846/QALY</cell><cell></cell><cell>$13,707/QALY</cell><cell></cell><cell>$13,784/QALY</cell><cell></cell><cell>$36,253/QALY</cell><cell></cell><cell>$8,855/QALY</cell><cell></cell><cell>$9,141/QALY</cell><cell>$57,438/QALY</cell><cell>Continued on p. 1562</cell></row><row><cell>Time horizon;</cell><cell>discount rate</cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell></cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Lifetime; 5%</cell><cell></cell><cell></cell><cell></cell><cell>Lifetime; 1.5%</cell><cell></cell><cell></cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell>Lifetime; 3%</cell><cell></cell><cell>Lifetime; 3%</cell><cell>Lifetime; 3%</cell></row><row><cell></cell><cell>Study method</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Computer simulation</cell><cell>(Sheffield T2D</cell><cell>Model) of LEADER</cell><cell>study cohort</cell><cell>Computer simulation</cell><cell>(Sheffield T2D</cell><cell>Model) of LEADER</cell><cell>study cohort</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell><cell>Computer simulation</cell><cell>(Archimedes)</cell></row><row><cell></cell><cell>Comparison</cell><cell></cell><cell>No screening and treatment</cell><cell>until clinical diagnosis of T2D</cell><cell></cell><cell></cell><cell>No screening or treatment until</cell><cell>clinical diagnosis of T2D</cell><cell></cell><cell>No screening or treatment until</cell><cell>clinical diagnosis of T2D</cell><cell></cell><cell>Targeted screening, then</cell><cell>treatment</cell><cell></cell><cell>No screening</cell><cell></cell><cell></cell><cell></cell><cell>No screening</cell><cell></cell><cell></cell><cell></cell><cell>No screening</cell><cell></cell><cell>No screening</cell><cell></cell><cell>No screening</cell><cell></cell><cell>No screening</cell><cell></cell><cell>No screening</cell><cell></cell><cell>No screening</cell><cell></cell><cell>No screening</cell><cell>No screening</cell></row><row><cell></cell><cell>Intervention</cell><cell></cell><cell>Opportunistic screening for</cell><cell>undiagnosed T2D starting at age</cell><cell>25 years, then treatment</cell><cell>(universal screening)</cell><cell>Targeted screening for undiagnosed</cell><cell>diabetes among persons with</cell><cell>hypertension</cell><cell>One-time opportunistic screening,</cell><cell>then treatment (universal</cell><cell>screening)</cell><cell>One-time opportunistic screening,</cell><cell>then treatment (universal</cell><cell>screening)</cell><cell>Prescreening with a risk score, then</cell><cell>screening with A1C test (cutoff of</cell><cell>6%)</cell><cell></cell><cell>Prescreening with a risk score, then</cell><cell>screening with FPG test (cutoff of</cell><cell>5.5 mmol)</cell><cell></cell><cell>T2D screening every 3 years starting</cell><cell>at age 30 years</cell><cell>T2D screening every 1 year starting</cell><cell>at age 45 years</cell><cell>T2D screening every 3 years starting</cell><cell>at age 45 years</cell><cell>T2D screening every 5 years starting</cell><cell>at age 45 years</cell><cell>T2D screening every 3 years starting</cell><cell>at age 60 years</cell><cell>T2D screening every 1 year following</cell><cell>hypertension diagnosis</cell><cell>T2D screening every 5 years following</cell><cell>hypertension diagnosis</cell><cell>T2D screening every 6 months starting</cell><cell>at age 30 years</cell></row><row><cell>Source (author,</cell><cell>year/country) Study population</cell><cell>Screening for undiagnosed T2D</cell><cell>Centers for U.S. population aged 25 years</cell><cell>Disease Control and older</cell><cell>and Prevention,</cell><cell>1998/U.S. (21)</cell><cell>Hoerger et al., Individuals with hypertension</cell><cell>2004/U.S. (22)</cell><cell></cell><cell>U.S. population</cell><cell></cell><cell></cell><cell>U.S. population</cell><cell></cell><cell></cell><cell>Gillett et al., 2015/ Adults aged 40-74 years with</cell><cell>U.K. (23) preDM and undiagnosed T2D</cell><cell></cell><cell></cell><cell>Adults aged 40-74 years with</cell><cell>preDM and undiagnosed T2D</cell><cell></cell><cell></cell><cell>Kahn et al., 2010/ U.S. population without DM,</cell><cell>U.S. (24) mean age 30 years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_YgCdQyb"><s xml:id="_2bSbwTq">SCIENTIFIC REVIEWDownloaded from http://diabetesjournals.org/care/article-pdf/43/7/1557/630574/dci200017.pdf by guest on 14 August 2025</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1558" xml:id="foot_1"><p xml:id="_bgxVsxJ"><s xml:id="_SzZsZvE">Cost-effectiveness of Diabetes Management Diabetes Care Volume 43, July 2020 Downloaded from http://diabetesjournals.org/care/article-pdf/43/7/1557/630574/dci200017.pdf by guest on 14 August 2025</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_3nn55nf"><s xml:id="_upPHfYS">Downloaded from http://diabetesjournals.org/care/article-pdf/43/7/1557/630574/dci200017.pdf by guest on 14 August 2025</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1560" xml:id="foot_3"><p xml:id="_DXqHEeA"><s xml:id="_HKUJNG2">Cost-effectiveness of Diabetes Management Diabetes Care Volume 43, July 2020 Downloaded from http://diabetesjournals.org/care/article-pdf/43/7/1557/630574/dci200017.pdf by guest on 14 August 2025</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1570" xml:id="foot_4"><p xml:id="_SgBhekA"><s xml:id="_MWD52tK">Cost-effectiveness of Diabetes Management Diabetes Care Volume 43, July 2020 Downloaded from http://diabetesjournals.org/care/article-pdf/43/7/1557/630574/dci200017.pdf by guest on 14 August 2025</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div xml:id="_9baKy2f"><p xml:id="_WjjZnrM"><s xml:id="_Ma5Veum">Acknowledgments.</s><s xml:id="_rQGRCXj">This work is a collaboration between the <rs type="institution">Centers for Disease Control and Prevention</rs> and the ADA.</s><s xml:id="_Zt69rGk">The authors thank the external and internal reviewers for their valuable comments during the review process.</s><s xml:id="_Y29twKf">The authors thank <rs type="person">Rui Li</rs> for generously sharing materials from her previous review and <rs type="person">William Thomas</rs> for his timely help with the literature search (both from <rs type="institution">Centers for Disease Control and Prevention)</rs>.</s><s xml:id="_MZYrHDq">Duality of Interest.</s><s xml:id="_JDVeZk2">No potential conflicts of interest relevant to this article were reported.</s></p></div>
			</div>			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_CtrtmKw" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Atlanta</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
		<respStmt>
			<orgName>Centers for Disease Control and Prevention, U.S. Department of Health and Human Services</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Atlanta, GA, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2017</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_kS3839J">Economic costs of diabetes in the U.S. in 2017</title>
		<author>
			<persName><forename type="first">American</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Association</forename></persName>
		</author>
		<idno type="DOI">10.2337/dci18-0007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xXSeePW">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="917" to="928" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018; 41:917-928</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_ZRWeEgZ">Standards of Medical Care in Diabetesd2020 abridged for primary care providers</title>
		<author>
			<persName><forename type="first">American</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Association</forename></persName>
		</author>
		<idno type="DOI">10.2337/cd20-as01</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fuWWQ77">Clin Diabetes</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="10" to="38" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">American Diabetes Association. Standards of Medical Care in Diabetesd2020 abridged for pri- mary care providers. Clin Diabetes 2020;38:10-38</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_XM23yDF">Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review</title>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tXzYsZN">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1872" to="1894" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic re- view. Diabetes Care 2010;33:1872-1894</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_9dNTWnm">Standards of medical care in diabetesd2008</title>
		<author>
			<persName><forename type="first">American</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Association</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Qxfubtn">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="12" to="S54" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>Suppl. 1</note>
	<note type="raw_reference">American Diabetes Association. Standards of medical care in diabetesd2008. Diabetes Care 2008;31(Suppl. 1):S12-S54</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_Kv2Utg3">Updates to the Standards of Medical Care in Diabetesd2018</title>
		<author>
			<persName><forename type="first">Association</forename><surname>American</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Diabetes</forename></persName>
		</author>
		<idno type="DOI">10.2337/dc18-su09</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_34hh8tZ">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="2045" to="2047" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Association American Diabetes. Updates to the Standards of Medical Care in Diabetesd2018. Diabetes Care 2018;41:2045-2047</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_usXf446">Standards of Medical Care in Diabetesd2019 abridged for primary care providers</title>
		<author>
			<persName><forename type="first">American</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Association</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yzpUHGe">Clin Diabetes</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="11" to="34" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">American Diabetes Association. Standards of Medical Care in Diabetesd2019 abridged for pri- mary care providers. Clin Diabetes 2019;37:11-34</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_AMdyAy2">Cochrane Reviewers&apos; Handbook 4.2.0</title>
		<author>
			<persName><forename type="first">M</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vMVxSb6">The Cochrane Libr</title>
		<imprint>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2003-03">March 2003. 2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clarke M, Oxman A., Eds. Cochrane Reviewers&apos; Handbook 4.2.0. [updated March 2003]. The Cochrane Libr 2003;(2)</note>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" xml:id="_YgXQSMe">World Bank Country and Lending Groups</title>
		<imprint>
			<publisher>The World Bank Group</publisher>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">The World Bank. World Bank Country and Lending Groups. The World Bank Group, 2017</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_myhAmCd">The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Jefferson</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.313.7052.275</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qD39FZs">BMJ</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="275" to="283" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>BMJ</note>
	<note type="raw_reference">Drummond MF, Jefferson TO; The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-283</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main" xml:id="_fD38beX">Consumer Price Index</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">S</forename></persName>
		</author>
		<ptr target="https://www.bls.gov/cpi/" />
		<imprint>
			<date type="published" when="2017-03-20">2017. 20 March 2018</date>
		</imprint>
		<respStmt>
			<orgName>Bureau of Labor Statistics</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">U.S. Bureau of Labor Statistics. Consumer Price Index, 2017. Available from https://www .bls.gov/cpi/. Accessed 20 March 2018</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<idno type="DOI">10.26509/frbc-wp-198908</idno>
		<ptr target="http://www.federalreserve.gov/releases/g5a/" />
		<title level="m" xml:id="_8MqzuXz">Foreign exchange rates</title>
		<imprint>
			<publisher>The Federal Reserve</publisher>
			<date type="published" when="2017-08-28">28 August 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">The Federal Reserve. Foreign exchange rates (annual). Available from http://www.federalreserve .gov/releases/g5a/. Accessed 28 August 2017</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_fVsuHW7">Introduction: Standards of Medical Care in Diabetesd2019</title>
		<author>
			<orgName type="collaboration">American Diabetes Association</orgName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2XBy7c4">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1" to="S2" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note>Suppl. 1</note>
	<note type="raw_reference">American Diabetes Association. Introduction: Standards of Medical Care in Diabetesd2019. Diabetes Care 2019;42(Suppl. 1):S1-S2</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_UAP8Py6">Summary of revisions: Standards of Medical Care in Diabetesd 2019</title>
		<author>
			<persName><forename type="first">American</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Association</forename></persName>
		</author>
		<idno type="DOI">10.2337/dc19-srev01</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Eq5N4aZ">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="4" to="S6" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note>Suppl. 1</note>
	<note type="raw_reference">American Diabetes Association. Summary of revisions: Standards of Medical Care in Diabetesd 2019. Diabetes Care 2019;42(Suppl. 1):S4-S6</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_fuanTqr">The importance of addressing depression and diabetes distress in adults with type 2 diabetes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Owens-Gary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jawanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Bullard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Allweiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Smith</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11606-018-4705-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GJUVguw">J Gen Intern Med</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="320" to="324" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Owens-Gary MD, Zhang X, Jawanda S, Bullard KM, Allweiss P, Smith BD. The importance of addressing depression and diabetes distress in adults with type 2 diabetes. J Gen Intern Med 2019;34:320-324</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_x6jxsVr">Achievement of goals in U.S. diabetes care, 1999-2010</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Bullard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmc1306652</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y32nEcf">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="287" to="288" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ali MK, Bullard KM, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013;369:287-288</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_cfS6SSh">A cascade of care for diabetes in the United States: visualizing the gaps</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Bullard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Rio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.7326/m14-0019</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qxtBwrg">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="681" to="689" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ali MK, Bullard KM, Gregg EW, Del Rio C. A cascade of care for diabetes in the United States: visualizing the gaps. Ann Intern Med 2014;161: 681-689</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_JpK3j9N">ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bowman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mafham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wallendszus</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa1804988</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_shVyTeH">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page" from="1529" to="1539" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bowman L, Mafham M, Wallendszus K, et al.; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:1529-1539</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_KcT24Cj">The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes &amp; Aging Study)</title>
		<author>
			<persName><forename type="first">N</forename><surname>Laiteerapong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Ham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HgSK45w">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="416" to="426" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes &amp; Aging Study). Diabetes Care 2019;42:416-426</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_6HadpUZ">Glycemic control in nonpregnant adults with type 2 diabetes</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Tung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Laiteerapong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tTtpwGD">JAMA</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope unit="page" from="2430" to="2431" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tung EL, Davis AM, Laiteerapong N. Glycemic control in nonpregnant adults with type 2 di- abetes. JAMA 2018;319:2430-2431</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_sUgzb2N">Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes</title>
		<author>
			<persName><surname>Cdc Diabetes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HMMYxGU">JAMA</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="1757" to="1763" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 di- abetes. JAMA 1998;280:1757-1763</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_YeYAH3W">Screening for type 2 diabetes mellitus: a cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hoerger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Donahue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sorensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Engelgau</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-140-9-200405040-00008</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aFeXEY8">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="689" to="699" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689-699</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_xZrFGG8">The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gillett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Watson</surname></persName>
		</author>
		<idno type="DOI">10.3310/hta19330</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7Jks36z">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1" to="80" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gillett M, Brennan A, Watson P, et al. The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technol Assess 2015;19:1-80</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_a7VV7fs">Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Alperin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eddy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BRysJCx">Lancet</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1365" to="1374" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-1374</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_GFQTvzb">Screening for gestational diabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Fleisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Powe</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.28.6.1482</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9yxFUCR">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1482" to="1484" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nicholson WK, Fleisher LA, Fox HE, Powe NR. Screening for gestational diabetes mellitus: a de- cision and cost-effectiveness analysis of four screen- ing strategies. Diabetes Care 2005;28:1482-1484</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_aGq2GKB">Screening for gestational diabetes mellitus: are the criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups costeffective?</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Pettker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zuckerwise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GMm9YkC">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="529" to="535" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Werner EF, Pettker CM, Zuckerwise L, et al. Screening for gestational diabetes mellitus: are the criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups cost- effective? Diabetes Care 2012;35:529-535</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_d5rXr94">Incremental cost-effectiveness analysis of gestational diabetes mellitus screening strategies in Singapore</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Finkelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ng</surname></persName>
		</author>
		<idno type="DOI">10.1177/1010539515612908</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PZvT52E">Asia Pac J Public Health</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="15" to="25" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chen PY, Finkelstein EA, Ng MJ, et al. In- cremental cost-effectiveness analysis of gesta- tional diabetes mellitus screening strategies in Singapore. Asia Pac J Public Health 2016;28:15-25</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_EwprvTy">The costeffectiveness of screening for gestational diabetes mellitus in primary and secondary care in the Republic of Ireland</title>
		<author>
			<persName><forename type="first">A</forename><surname>Danyliv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RWUcqpc">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="436" to="444" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Danyliv A, Gillespie P, O&apos;Neill C, et al. The cost- effectiveness of screening for gestational diabetes mellitus in primary and secondary care in the Republic of Ireland. Diabetologia 2016;59:436-444</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_nPCtuzT">Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial</title>
		<author>
			<persName><forename type="first">The</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Control</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Complications</forename><surname>Trial</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Research</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jwMWUBb">JAMA</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="page" from="1409" to="1415" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of in- tensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409-1415</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_qHPrkcH">Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Eastman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Javitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Herman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p3yCU5d">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="735" to="744" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-744</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_kMzMGBc">United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raikou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcguire</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9a9ARjq">BMJ</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="1373" to="1378" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gray A, Raikou M, McGuire A, et al.; United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000;320:1373-1378</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_aHUNSET">The costeffectiveness of different management strategies for type I diabetes: a Swiss perspective</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Sendi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s001250050003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AYttCA2">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="13" to="26" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Palmer AJ, Weiss C, Sendi PP, et al. The cost- effectiveness of different management strate- gies for type I diabetes: a Swiss perspective. Diabetologia 2000;43:13-26</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_nYfZY8n">Costeffectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study</title>
		<author>
			<persName><forename type="first">N</forename><surname>Wake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hisashige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Katayama</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0168-8227(00)00122-4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UNASVGV">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="201" to="210" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wake N, Hisashige A, Katayama T, et al. Cost- effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000;48:201-210</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_THzQHEx">Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Adler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ysna2Kg">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="298" to="304" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clarke P, Gray A, Adler A, et al.; UKPDS Group. Cost-effectiveness analysis of intensive blood-glucose control with metformin in over- weight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001;44:298-304</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_BYnns9t">Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes</title>
		<author>
			<persName><forename type="first">Cost-Effectiveness</forename><surname>Cdc Diabetes</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PkzSEsb">JAMA</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="2542" to="2551" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cho- lesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_YWZN2Pm">The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Scuffham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Carr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YHuZBzs">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="586" to="593" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003;20:586-593</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_RWEExJ4">Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK</title>
		<author>
			<persName><forename type="first">S</forename><surname>Roze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Valentine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Zakrzewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Palmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9Cg6awb">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1239" to="1245" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet Med 2005;22:1239-1245</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_RSWaJsh">UKPDS 72 United Kingdom Prospective Diabetes Study. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Briggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Holman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M4kMufM">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="868" to="877" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR; UKPDS 72 United Kingdom Prospective Diabetes Study. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-877</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_EbfaGua">Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Eddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schlessinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ddQjtsm">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="251" to="264" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-264</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_KqfmbsC">Cost-effectiveness of insulin analogues for diabetes mellitus</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Bennett</surname></persName>
		</author>
		<idno type="DOI">10.1503/cmaj.081180</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_A37gUaZ">CMAJ</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="page" from="400" to="407" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009;180:400-407</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_b2CVtgA">Costeffectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salkeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZyatCEt">Value Health</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="196" to="208" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Howard K, White S, Salkeld G, et al. Cost- effectiveness of screening and optimal manage- ment for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health 2010;13:196-208</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_2uC8GdR">Costeffectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Klarenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ur</surname></persName>
		</author>
		<idno type="DOI">10.1503/cmaj.110178</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ec3NjH7">CMAJ</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="1213" to="E1220" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klarenbach S, Cameron C, Singh S, Ur E. Cost- effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ 2011;183:E1213-E1220</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_Yk42Apt">Managing glycaemia in older people with type 2 diabetes: a retrospective, primary carebased cohort study, with economic assessment of patient outcomes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mcewan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Puelles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sinclair</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9sNBgfD">Diabetes Obes Metab</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="644" to="653" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care- based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab 2017;19:644-653</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_hA7ejMq">Cost effectiveness of self monitoring of blood glucose in patients with noninsulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A;</forename><surname>Farmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Glycaemic</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Monitoring</forename><surname>Education</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Group</forename><surname>Trial</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.39526.674873.be</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_quyxDsM">BMJ</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="1177" to="1180" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A; Diabetes Glycaemic Education and Monitoring Trial Group. Cost effectiveness of self monitoring of blood glucose in patients with non- insulin treated type 2 diabetes: economic eval- uation of data from the DiGEM trial. BMJ 2008; 336:1177-1180</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_kKg5XtQ">Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Tunis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Minshall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4J382sv">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="131" to="140" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states. Am J Manag Care 2008;14:131-140</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_zrkqmGZ">Costeffectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Coyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Klarenbach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VqNX8cs">CMAJ</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="page" from="28" to="34" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cameron C, Coyle D, Ur E, Klarenbach S. Cost- effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus man- aged without insulin. CMAJ 2010;182:28-34</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_fvBNnmk">Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Pollock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Valentine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Goodall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>BrÃ¤ndle</surname></persName>
		</author>
		<idno type="DOI">10.4414/smw.2010.13103</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_S8vUrDq">Swiss Med Wkly</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page">13103</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pollock RF, Valentine WJ, Goodall G, BrÃ¤ndle M. Evaluating the cost-effectiveness of self-mon- itoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. Swiss Med Wkly 2010; 140:w13103</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_YgvUXUj">Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Tunis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Minshall</surname></persName>
		</author>
		<idno type="DOI">10.1185/03007990903400071</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_32fayNw">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="151" to="162" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tunis SL, Minshall ME. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. Curr Med Res Opin 2010;26:151-162</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_bpCkGgc">Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: costeffectiveness in France, Germany, Italy, and Spain</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Tunis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Willis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Foos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TkfD8Np">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="163" to="175" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tunis SL, Willis WD, Foos V. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost- effectiveness in France, Germany, Italy, and Spain. Curr Med Res Opin 2010;26:163-175</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_ywB7gBF">Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Tunis</surname></persName>
		</author>
		<idno type="DOI">10.2165/11594270-000000000-00000</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xbkEf3T">Appl Health Econ Health Policy</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="351" to="365" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tunis SL. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings. Appl Health Econ Health Policy 2011;9:351-365</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_d6H8J7c">Economic value of improved accuracy for self-monitoring of blood glucose devices for type 1 diabetes in Canada</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Mcqueen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Breton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Beamer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Campbell</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296815599551</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rrxAY9w">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="366" to="377" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McQueen RB, Breton MD, Ott M, Koa H, Beamer B, Campbell JD. Economic value of improved accuracy for self-monitoring of blood glucose devices for type 1 diabetes in Canada. J Diabetes Sci Technol 2015;10:366-377</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_bHKGqBZ">Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40</title>
		<author>
			<persName><forename type="first">Diabetes</forename><surname>Uk Prospective</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Group</forename><surname>Study</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M9FKSXB">BMJ</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page" from="720" to="726" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pres- sure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317:720-726</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_hjzHDaU">Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Weir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Black</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinte.160.9.1277</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7Nwxp6u">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="1277" to="1283" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evalua- tion, and Treatment of High Blood Pressure. Arch Intern Med 2000;160:1277-1283</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_AtwPrF7">Cost effectiveness analysis of a hypertension management program in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Z</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hebert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_m2eeHhX">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="116" to="124" />
			<date type="published" when="2009">2009</date>
			<pubPlace>Greenwich</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Ly D, Fu AZ, Hebert C. Cost effectiveness analysis of a hypertension management program in patients with type 2 diabetes. J Clin Hypertens (Greenwich) 2009;11:116-124</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_Rb7TjPM">Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Cook</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.22.11.1771</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QAzssgT">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1771" to="1778" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 1999; 22:1771-1778</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_98AVUdv">The costeffectiveness of lipid lowering in patients with diabetes: results from the 4S trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>JÃ¶nsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Pedersen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s001250051441</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_y2VT74a">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1293" to="1301" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">JÃ¶nsson B, Cook JR, Pedersen TR. The cost- effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42:1293-1301</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_PAqCVzk">Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Coupal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zowall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dorais</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.cir.102.7.722</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bAcyF4F">Circulation</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="722" to="727" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000;102:722-727</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_bA4vmDg">CARDS Investigators. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Raikou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Colhoun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3hPHW4S">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="733" to="740" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raikou M, McGuire A, Colhoun HM, et al.; CARDS Investigators. Cost-effectiveness of pri- mary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50:733-740</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_j6HsZGs">Model-based simulation to explore the costeffectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Sorensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Frick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Simko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Burge</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clinthera.2009.04.015</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Em3hbGp">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="862" to="879" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sorensen SV, Frick KD, Wade A, Simko R, Burge R. Model-based simulation to explore the cost- effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Clin Ther 2009;31:862-879</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_DgSPD2Z">Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>De Vries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Denig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Postma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vxauNuP">Value Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="223" to="230" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">de Vries FM, Denig P, Visser ST, Hak E, Postma MJ. Cost-effectiveness of statins for primary pre- vention in patients newly diagnosed with type 2 diabetes in the Netherlands. Value Health 2014; 17:223-230</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_vXYNkNH">Optimal allocation of resources across four interventions for type 2 diabetes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Earnshaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Sorensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M223Wtu">Med Decis Making</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="80" to="S91" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
	<note type="raw_reference">Earnshaw SR, Richter A, Sorensen SW, et al. Optimal allocation of resources across four inter- ventions for type 2 diabetes. Med Decis Making 2002;22(Suppl):S80-S91</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_6HZm9wJ">Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting</title>
		<author>
			<persName><forename type="first">V</forename><surname>Gozzoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brandt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Spinas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_R689AWk">Swiss Med Wkly</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="303" to="310" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gozzoli V, Palmer AJ, Brandt A, Spinas GA. Economic and clinical impact of alternative dis- ease management strategies for secondary pre- vention in type 2 diabetes in the Swiss setting. Swiss Med Wkly 2001;131:303-310</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_K63VJuw">Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with type 1 diabetes in the UK</title>
		<author>
			<persName><forename type="first">A</forename><surname>Shearer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bagust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sanderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cx4CRAG">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="460" to="467" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shearer A, Bagust A, Sanderson D, Heller S, Roberts S. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with type 1 diabetes in the UK. Diabet Med 2004;21:460-467</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_hRSctMH">Cost-effectiveness of diabetes self-management programs in community primary care settings</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Brownson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hoerger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Kilpatrick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SHscGcu">Diabetes Educ</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="761" to="769" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brownson CA, Hoerger TJ, Fisher EB, Kilpatrick KE. Cost-effectiveness of diabetes self-management programs in community primary care settings. Diabetes Educ 2009;35:761-769</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_JB4xm6c">Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gillett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Dallosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dixon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aZHu7mJ">BMJ</title>
		<imprint>
			<biblScope unit="volume">341</biblScope>
			<biblScope unit="page">4093</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gillett M, Dallosso HM, Dixon S, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) pro- gramme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ 2010; 341:c4093</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_Awt2mN6">Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Shea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dinneen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Irish Dafne Study</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_K3h8KWN">Trials</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">227</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gillespie P, O&apos;Shea E, O&apos;Hara MC, Dinneen SF, Irish DAFNE Study Group. Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial. Trials 2014;15:227</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_G5nb98k">The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kruger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thokala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PTRnqUz">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1236" to="1244" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kruger J, Brennan A, Thokala P, et al. The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model. Diabet Med 2013;30: 1236-1244</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_eTffatF">A cost-effectiveness analysis of a telephone-linked care intervention for individuals with type 2 diabetes</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Oldenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Scuffham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bknVRJ8">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="103" to="111" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gordon LG, Bird D, Oldenburg B, Friedman RH, Russell AW, Scuffham PA. A cost-effectiveness analysis of a telephone-linked care intervention for individuals with type 2 diabetes. Diabetes Res Clin Pract 2014;104:103-111</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_XfCa3QU">The Community Diabetes Education (CoDE) program: cost-effectiveness and health outcomes</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Prezio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>PagÃ¡n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shuval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Culica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qkKVttr">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="771" to="779" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Prezio EA, PagÃ¡n JA, Shuval K, Culica D. The Community Diabetes Education (CoDE) program: cost-effectiveness and health outcomes. Am J Prev Med 2014;47:771-779</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_FMy7Zup">Cost-effectiveness of community health workers in controlling diabetes epidemic on the U.S.-Mexico border</title>
		<author>
			<persName><forename type="first">I</forename><surname>Ryabov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZSkzX3E">Public Health</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="636" to="642" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ryabov I. Cost-effectiveness of community health workers in controlling diabetes epidemic on the U.S.-Mexico border. Public Health 2014; 128:636-642</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_GmDb5zB">The cost-effectiveness of hospitalbased telephone coaching for people with type 2 diabetes: a 10 year modelling analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Varney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Liew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Weiland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Inder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Jelinek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_REUhpGZ">BMC Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">521</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Varney JE, Liew D, Weiland TJ, Inder WJ, Jelinek GA. The cost-effectiveness of hospital- based telephone coaching for people with type 2 diabetes: a 10 year modelling analysis. BMC Health Serv Res 2016;16:521</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_sw7deY9">Delivering diabetes education through nurse-led telecoaching. costeffectiveness analysis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Odnoletkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ramaekers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nobels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Goderis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Aertgeerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Annemans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NE2djnZ">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">163997</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Odnoletkova I, Ramaekers D, Nobels F, Goderis G, Aertgeerts B, Annemans L. Delivering diabetes education through nurse-led telecoaching. cost- effectiveness analysis. PLoS One 2016;11:e0163997</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_3cQYHC5">Costeffectiveness of aspirin use among persons with newly diagnosed type 2 diabetes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hoerger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_E4Sv93Y">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1193" to="1199" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li R, Zhang P, Barker LE, Hoerger TJ. Cost- effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care 2010;33:1193-1199</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_MXUgzkC">Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">A</forename><surname>Van Giessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Boonman-De</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Rutten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_w9r4gqQ">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">48</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van Giessen A, Boonman-de Winter LJ, Rutten FH, et al. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovasc Diabetol 2016;15:48</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main" xml:id="_4sD83jC">Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Javitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Aiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Ferris</surname></persName>
		</author>
		<author>
			<persName><surname>Iii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Canner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Greenfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9Vvfe9v">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="909" to="917" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Javitt JC, Aiello LP, Chiang Y, Ferris FL III, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994;17:909-917</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main" xml:id="_Q9hzWNs">Cost-effectiveness of detecting and treating diabetic retinopathy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Javitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Aiello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KHD9BFy">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="164" to="169" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Javitt JC, Aiello LP. Cost-effectiveness of de- tecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164-169</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main" xml:id="_aUagVHp">Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">S</forename><surname>Vijan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Hayward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_myVFQry">JAMA</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="889" to="896" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic ret- inopathy in patients with type 2 diabetes melli- tus. JAMA 2000;283:889-896</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main" xml:id="_DsUkDzc">Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Maberley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Koushik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cruess</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ej6RGUv">CMAJ</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="160" to="164" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Maberley D, Walker H, Koushik A, Cruess A. Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. CMAJ 2003; 168:160-164</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main" xml:id="_xrMdnhr">Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kirkizlar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Serban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sisson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Swann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Barnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KYupBM5">Ophthalmology</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="2604" to="2610" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD. Evaluation of teleme- dicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology 2013;120:2604-2610</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main" xml:id="_krsu3c6">Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Gangwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mcghee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Wtv2fer">Ophthalmology</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="2278" to="2285" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chan CK, Gangwani RA, McGhee SM, Lian J, Wong DS. Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening. Ophthal- mology 2015;122:2278-2285</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main" xml:id="_MM2wn9d">Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kawasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Akune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hiratsuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fukuhara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yamada</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fTrv2Qh">Ophthalmic Epidemiol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="4" to="12" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kawasaki R, Akune Y, Hiratsuka Y, Fukuhara S, Yamada M. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study. Ophthalmic Epidemiol 2015;22:4-12</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main" xml:id="_qfPmzYD">Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Scanlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Aldington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CmhB7yH">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1" to="116" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scanlon PH, Aldington SJ, Leal J, et al. De- velopment of a cost-effectiveness model for optimisation of the screening interval in di- abetic retinopathy screening. Health Technol Assess 2015;19:1-116</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main" xml:id="_FZxWhtC">Incremental cost-effectiveness of algorithmdriven genetic testing versus no testing for maturity onset diabetes of the young (MODY) in Singapore</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">V</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Finkelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Gardner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jFdq2P8">J Med Genet</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="747" to="753" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nguyen HV, Finkelstein EA, Mital S, Gardner DS. Incremental cost-effectiveness of algorithm- driven genetic testing versus no testing for ma- turity onset diabetes of the young (MODY) in Singapore. J Med Genet 2017;54:747-753</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main" xml:id="_c2C2ZT9">Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland</title>
		<author>
			<persName><forename type="first">G</forename><surname>Scotland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mckeigue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Philip</surname></persName>
		</author>
		<idno type="DOI">10.1111/dme.13129</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BHxj8PQ">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="886" to="895" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scotland G, McKeigue P, Philip S, et al. Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. Diabet Med 2016;33:886-895</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main" xml:id="_XQKcbev">Costutility analysis of extending public health insurance coverage to include diabetic retinopathy screening by optometrists</title>
		<author>
			<persName><forename type="first">S</forename><surname>Van Katwyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Trope</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2017.04.015</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wex2D99">Value Health</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1034" to="1040" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van Katwyk S, Jin YP, Trope GE, et al. Cost- utility analysis of extending public health in- surance coverage to include diabetic retinopathy screening by optometrists. Value Health 2017; 20:1034-1040</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main" xml:id="_SaSgRCN">Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations</title>
		<author>
			<persName><forename type="first">Ragnarson</forename><surname>Tennvall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Apelqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_547MWZy">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="2077" to="2087" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ragnarson Tennvall G, Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 2001;44:2077-2087</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main" xml:id="_9XgxE2E">Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Ortegon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Redekop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Niessen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Gqad5Ja">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="901" to="907" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ortegon MM, Redekop WK, Niessen LW. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care 2004;27:901-907</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main" xml:id="_GBFCUPu">Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Borch-Johnsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wenzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Viberti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Mogensen</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.306.6894.1722</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vnnRUsH">BMJ</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="page" from="1722" to="1725" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993; 306:1722-1725</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main" xml:id="_WNafCzJ">Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Kiberd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Jindal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3rcee2x">BMJ</title>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="page" from="1595" to="1599" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic pa- tients: an economic evaluation. BMJ 1995;311: 1595-1599</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main" xml:id="_rf3EJeR">The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors</title>
		<author>
			<persName><forename type="first">L</forename><surname>Golan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Birkmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Welch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_89PdbyV">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="660" to="667" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131: 660-667</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main" xml:id="_QmBHppR">To pay or not to pay? A decision and cost-utility analysis of angiotensin-convertingenzyme inhibitor therapy for diabetic nephropathy</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Churchill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Forwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Foster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SRsKYdK">CMAJ</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="195" to="198" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting- enzyme inhibitor therapy for diabetic nephrop- athy. CMAJ 2000;162:195-198</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main" xml:id="_4ZDYamP">An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Annemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Roze</forename><forename type="middle">S</forename><surname>Lamotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rodby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Cordonnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jN6fNVZ">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2059" to="2066" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. An economic evalu- ation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephrop- athy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003; 18:2059-2066</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main" xml:id="_KzxpAN5">An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France</title>
		<author>
			<persName><forename type="first">T</forename><surname>Souchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Durand</forename><surname>Zaleski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hannedouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rodier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gaugris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Passa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P; Renaal</forename><surname>Study</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qSQzckt">Diabetes Metab</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="29" to="35" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Souchet T, Durand Zaleski I, Hannedouche T, Rodier M, Gaugris S, Passa P; RENAAL study. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab 2003;29:29-35 107.</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main" xml:id="_tEsKGTW">Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Freemantle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jp; Splint</forename><surname>New</surname></persName>
		</author>
		<author>
			<persName><surname>Trial</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.28.1.40</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BbgDMPY">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="40" to="46" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mason JM, Freemantle N, Gibson JM, New JP; SPLINT trial. Specialist nurse-led clinics to improve control of hypertension and hyperlip- idemia in diabetes: economic analysis of the SPLINT trial. Diabetes Care 2005;28:40-46 108.</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main" xml:id="_bMenEWJ">Costeffectiveness of diabetes case management for low-income populations</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Gilmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Roze</forename><forename type="middle">S</forename><surname>Valentine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WkhzFvA">Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1943" to="1959" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gilmer TP, Roze S, Valentine WJ, et al. Cost- effectiveness of diabetes case management for low-income populations. Health Serv Res 2007; 42:1943-1959 109.</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main" xml:id="_2WTYygk">A cost effectiveness study of integrated care in health services delivery: a diabetes program in Australia</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Mcrae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Sibthorpe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zb33HgN">BMC Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="205" to="110" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McRae IS, Butler JR, Sibthorpe BM, et al. A cost effectiveness study of integrated care in health services delivery: a diabetes program in Australia. BMC Health Serv Res 2008;8:205 110.</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main" xml:id="_JQ7UEwG">Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Schouten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Niessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Van De Pas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Grol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hulscher</surname></persName>
		</author>
		<idno type="DOI">10.1097/mlr.0b013e3181eb318f</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PKJmkwP">Med Care</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="884" to="891" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schouten LM, Niessen LW, van de Pas JW, Grol RP, Hulscher ME. Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes. Med Care 2010;48:884-891 111.</note>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main" xml:id="_d2USmub">Cost-effectiveness of implementing the chronic care model for diabetes care in a military population</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Bryce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Zgibor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<idno type="DOI">10.1177/193229681100500305</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CWxxyA3">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="501" to="513" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kuo S, Bryce CL, Zgibor JC, Wolf DL, Roberts MS, Smith KJ. Cost-effectiveness of implement- ing the chronic care model for diabetes care in a military population. J Diabetes Sci Technol 2011; 5:501-513 112.</note>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main" xml:id="_VHgSGaq">A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia</title>
		<author>
			<persName><forename type="first">Haji</forename><surname>Ali Afzali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beilby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Holton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Karnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KmagBuV">Appl Health Econ Health Policy</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="661" to="670" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Haji Ali Afzali H, Gray J, Beilby J, Holton C, Karnon J. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia. Appl Health Econ Health Policy 2013;11:661-670 113.</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main" xml:id="_W8p6SA8">Stratified patient-centered care in type 2 diabetes: a cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Slingerland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Redekop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Dijkstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Jukema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Niessen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aVeZR5c">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="3054" to="3061" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Slingerland AS, Herman WH, Redekop WK, Dijkstra RF, Jukema JW, Niessen LW. Stratified patient-centered care in type 2 diabetes: a clus- ter-randomized, controlled clinical trial of effec- tiveness and cost-effectiveness. Diabetes Care 2013;36:3054-3061 114.</note>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main" xml:id="_dcZcVfm">A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Ip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6RTnaD4">J Manag Care Pharm</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="102" to="114" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yu J, Shah BM, Ip EJ, Chan J. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern Cal- ifornia. J Manag Care Pharm 2013;19:102-114 115.</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main" xml:id="_KmYPFV5">Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tsiachristas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Cramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Nieboer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Rutten-Van MÃ¶lken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7s8KTKE">Cost Eff Resour Alloc</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="17" to="116" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tsiachristas A, Cramm JM, Nieboer AP, Rutten-van MÃ¶lken MP. Changes in costs and effects after the implementation of disease man- agement programs in the Netherlands: variability and determinants. Cost Eff Resour Alloc 2014;12:17 116.</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main" xml:id="_sszSp4a">ICCD trial group. Evaluation of the clinical and cost effectiveness of intermediate care clinics for diabetes (ICCD): a multicentre cluster randomised controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Hare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hardy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0093964</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FSzJsst">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="93964" to="93117" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wilson A, O&apos;Hare JP, Hardy A, et al.; ICCD trial group. Evaluation of the clinical and cost effectiveness of intermediate care clinics for di- abetes (ICCD): a multicentre cluster randomised controlled trial. PLoS One 2014;9:e93964 117.</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main" xml:id="_DMHPS3m">Costeffectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Wareham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p3vgZ6t">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="907" to="919" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tao L, Wilson EC, Wareham NJ, et al. Cost- effectiveness of intensive multifactorial treat- ment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med 2015;32:907-919 118.</note>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main" xml:id="_jqwSkUd">Estimated cost-effectiveness, cost benefit, and risk reduction associated with an endocrinologist-pharmacist Diabetes Intense Medical Management &quot;Tune-Up&quot; clinic</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hirsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bounthavong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arjmand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jtqcMaz">J Manag Care Spec Pharm</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="318" to="326" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hirsch JD, Bounthavong M, Arjmand A, et al. Estimated cost-effectiveness, cost benefit, and risk reduction associated with an endocrinolo- gist-pharmacist Diabetes Intense Medical Man- agement &quot;Tune-Up&quot; clinic. J Manag Care Spec Pharm 2017;23:318-326 119.</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main" xml:id="_avw77Sc">Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Cobden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Niessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Rutten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Redekop</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RnWfXZv">Patient Prefer Adherence</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="283" to="290" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cobden DS, Niessen LW, Rutten FF, Redekop WK. Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical ap- proach. Patient Prefer Adherence 2010;4:283-290 120.</note>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main" xml:id="_qY4856n">Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Cleveringa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Welsing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Den Donk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xMD558Y">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="258" to="263" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cleveringa FG, Welsing PM, van den Donk M, et al. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. Diabetes Care 2010; 33:258-263 121.</note>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main" xml:id="_xweWXnU">Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records</title>
		<author>
			<persName><forename type="first">D</forename><surname>O'reilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Holbrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Blackhouse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Troyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Goeree</surname></persName>
		</author>
		<idno type="DOI">10.1136/amiajnl-2011-000371</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pzWUBTH">J Am Med Inform Assoc</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="341" to="345" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Reilly D, Holbrook A, Blackhouse G, Troyan S, Goeree R. Cost-effectiveness of a shared computerized decision support system for diabe- tes linked to electronic medical records. J Am Med Inform Assoc 2012;19:341-345 122.</note>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main" xml:id="_KNTctHw">Skrepnek GH Cost-effectiveness of medication therapy management in Part D diabetic enrollees</title>
		<author>
			<persName><forename type="first">E</forename><surname>Olvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Guy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chang</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p8y2phx">Am J Pharm Benefits</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="147" to="e156" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Olvey E, Guy MC, Chang J, Skrepnek GH Cost-effectiveness of medication therapy man- agement in Part D diabetic enrollees. Am J Pharm Benefits 2014;6:e147-e156 123.</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main" xml:id="_CET4Nyx">Cost effectiveness of peer support for type 2 diabetes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Shea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Dowd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1017/s0266462311000663</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nZWqypR">Int J Technol Assess Health Care</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="3" to="11" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gillespie P, O&apos;Shea E, Paul G, O&apos;Dowd T, Smith SM. Cost effectiveness of peer support for type 2 diabetes. Int J Technol Assess Health Care 2012;28:3-11 124.</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main" xml:id="_fmusvqg">Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hlatky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Boothroyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Melsop</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BeJKGvK">Circulation</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="2550" to="2558" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hlatky MA, Boothroyd DB, Melsop KA, et al.; Bypass Angioplasty Revascularization Investiga- tion 2 Diabetes (BARI 2D) Study Group. Economic outcomes of treatment strategies for type 2 di- abetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investiga- tion 2 Diabetes trial. Circulation 2009;120: 2550-2558 125.</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main" xml:id="_BZTupv3">The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hollands</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2zvUDPv">Curr Opin Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="230" to="234" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 2001;12:230-234 126.</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main" xml:id="_RmfRqxC">Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Annemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gallagher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rj2fMZ3">Br J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="688" to="693" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 2012;96:688-693 127.</note>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main" xml:id="_hqNMww3">Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a Diabetic Retinopathy Clinical Research Network randomized clinical trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Hutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Bressler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Jampol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Browning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Glassman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Retinopathy</forename><surname>Diabetic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Research</forename><surname>Clinical</surname></persName>
		</author>
		<author>
			<persName><surname>Network</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Hn6R7Vq">JAMA Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="576" to="584" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hutton DW, Stein JD, Bressler NM, Jampol LM, Browning D, Glassman AR; Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of intravitreous ranibizumab compared with panreti- nal photocoagulation for proliferative diabetic ret- inopathy: secondary analysis from a Diabetic Retinopathy Clinical Research Network random- ized clinical trial. JAMA Ophthalmol 2017;135: 576-584 128.</note>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main" xml:id="_HXAAjzh">A model to analyse costs and benefit of intensified diabetic foot care in Austria</title>
		<author>
			<persName><forename type="first">W</forename><surname>Habacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rakovac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>GÃ¶rzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5DNckVu">J Eval Clin Pract</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="906" to="912" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Habacher W, Rakovac I, GÃ¶rzer E, et al. A model to analyse costs and benefit of intensified diabetic foot care in Austria. J Eval Clin Pract 2007;13:906-912 129.</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main" xml:id="_zXeCV7p">A costutility comparison of four first-line medications in painful diabetic neuropathy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>O'connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Noyes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Holloway</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jqasN4R">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1045" to="1064" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Connor AB, Noyes K, Holloway RG. A cost- utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconom- ics 2008;26:1045-1064 130.</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main" xml:id="_HhPydkP">A costeffectiveness analysisof optimal carefor diabetic foot ulcers in Australia</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Lazzarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gibb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Tmr7Acw">Int Wound J</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="616" to="628" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cheng Q, Lazzarini PA, Gibb M, et al. A cost- effectiveness analysisof optimal carefor diabetic foot ulcers in Australia. Int Wound J 2017;14:616-628 131.</note>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main" xml:id="_QU96mCj">Cost-effectiveness and budget impact of obesity surgery in patients with type 2 diabetes in three European countries(II)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Anselmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">FernÃ¡ndez</forename><surname>CebriÃ¡n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Daoudf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Torresa</forename><surname>Romagnolig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j4EhNCF">Obes Surg</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1542" to="1549" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Anselmino M, Bammer T, FernÃ¡ndez CebriÃ¡n JM,DaoudF,RomagnoliG,TorresA.Cost-effectiveness and budget impact of obesity surgery in patients with type 2 diabetes in three European countries(II). Obes Surg 2009;19:1542-1549 132.</note>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main" xml:id="_Fv5GM9P">Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ikramuddin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klingman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Swan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Minshall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GtG6D8c">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="607" to="615" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ikramuddin S, Klingman D, Swan T, Minshall ME. Cost-effectiveness of Roux-en-Y gastric by- pass in type 2 diabetes patients. Am J Manag Care 2009;15:607-615 133.</note>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main" xml:id="_7Dk6Ya9">Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Moodie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DR7BGyQ">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="567" to="574" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care 2009; 32:567-574 134.</note>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main" xml:id="_G26S3wr">Cost-effectiveness of bariatric surgery for severely obese adults with diabetes</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hoerger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Segel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Couper</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc10-0554</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UUsqv6V">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1933" to="1939" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hoerger TJ, Zhang P, Segel JE, Kahn HS, Barker LE, Couper S. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 2010;33:1933-1939 135.</note>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main" xml:id="_pz6cAk8">Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Pollock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Muduma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Valentine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ErP3rP5">Diabetes Obes Metab</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="121" to="129" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pollock RF, Muduma G, Valentine WJ. Evalu- ating the cost-effectiveness of laparoscopic adjust- able gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. Diabetes Obes Metab 2013;15:121-129 136.</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main" xml:id="_GKf9sDV">Bariatric surgery can lead to net cost savings to health care systems: results from a comprehensive European decision analytic model</title>
		<author>
			<persName><forename type="first">O</forename><surname>Borisenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Adam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Funch-Jensen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11695-014-1567-5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wC5bZ9s">Obes Surg</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1559" to="1568" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Borisenko O, Adam D, Funch-Jensen P, et al. Bariatric surgery can lead to net cost savings to health care systems: results from a comprehen- sive European decision analytic model. Obes Surg 2015;25:1559-1568 137.</note>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main" xml:id="_nFb8mgm">Cost-utility analysis for bariatric surgery compared with usual care for the treatment of obesity in Australia</title>
		<author>
			<persName><forename type="first">R</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Salton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Byrnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Scuffham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xGMyH2f">Surg Obes Relat Dis</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2012" to="2020" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">James R, Salton RI, Byrnes JM, Scuffham PA. Cost-utility analysis for bariatric surgery compared with usual care for the treatment of obesity in Australia. Surg Obes Relat Dis 2017; 13:2012-2020 138.</note>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main" xml:id="_K3yTY2E">Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Wentworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Dalziel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nUJtb2s">J Diabetes Complications</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1139" to="1144" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wentworth JM, Dalziel KM, O&apos;Brien PE, et al. Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S. J Diabetes Complications 2017;31:1139-1144 139.</note>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main" xml:id="_VUH95Rv">Costeffectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression</title>
		<author>
			<persName><forename type="first">W</forename><surname>Katon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>UnÃ¼tzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Fan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_J4fNhwF">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="265" to="270" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Katon W, UnÃ¼tzer J, Fan MY, et al. Cost- effectiveness and net benefit of enhanced treat- ment of depression for older adults with diabetes and depression. Diabetes Care 2006;29:265-270 140.</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main" xml:id="_h8FWeF8">Cost-effectiveness evaluation of collaborative care for diabetes and depression in primary care</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soprovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Al</forename><surname>Sayah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_S3ynMbF">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="13" to="e20" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Johnson JA, Lier DA, Soprovich A, Al Sayah F, Qiu W, Majumdar SR. Cost-effectiveness evalua- tion of collaborative care for diabetes and de- pression in primary care. Am J Prev Med 2016;51: e13-e20 141.</note>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main" xml:id="_5NB54mf">The costeffectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation</title>
		<author>
			<persName><forename type="first">B</forename><surname>Kearns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rafia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leaviss</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12913-017-2003-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_prZswxH">BMC Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="78" to="142" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kearns B, Rafia R, Leaviss J, et al. The cost- effectiveness of changes to the care pathway used to identify depression and provide treat- ment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Serv Res 2017;17:78 142.</note>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main" xml:id="_wYCCDnm">Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Guest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Panca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sladkevicius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Taheri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stradling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xHGxmbg">Cost-effectiveness of Diabetes Management Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1263" to="1271" />
			<date type="published" when="2014-07">2014. July 2020</date>
		</imprint>
	</monogr>
	<note>Diabetes Care</note>
	<note type="raw_reference">Guest JF, Panca M, Sladkevicius E, Taheri S, Stradling J. Clinical outcomes and cost-effectiveness of continuous positive airway pressure to man- age obstructive sleep apnea in patients with type 2 diabetes in the U.K. Diabetes Care 2014;37: 1263-1271 1592 Cost-effectiveness of Diabetes Management Diabetes Care Volume 43, July 2020</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
